Peruvian American Endowment Evaluation

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome.	Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome. - 5	Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome. - 4	Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome. - 3	Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome. - 2	Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome. - 1	Apply evidence-based medical treatment to patients diagnosed with Pediatric Acute Respiratory Distress Syndrome. - 0
Assess benefit and risk associated with new therapies for inflammatory bowel disease.	Assess benefit and risk associated with new therapies for inflammatory bowel disease. - 5	Assess benefit and risk associated with new therapies for inflammatory bowel disease. - 4	Assess benefit and risk associated with new therapies for inflammatory bowel disease. - 3	Assess benefit and risk associated with new therapies for inflammatory bowel disease. - 2	Assess benefit and risk associated with new therapies for inflammatory bowel disease. - 1	Assess benefit and risk associated with new therapies for inflammatory bowel disease. - 0
Identify the most common comorbidities of childhood obesity and describe their pathophysiologies.	Identify the most common comorbidities of childhood obesity and describe their pathophysiologies. - 5	Identify the most common comorbidities of childhood obesity and describe their pathophysiologies. - 4	Identify the most common comorbidities of childhood obesity and describe their pathophysiologies. - 3	Identify the most common comorbidities of childhood obesity and describe their pathophysiologies. - 2	Identify the most common comorbidities of childhood obesity and describe their pathophysiologies. - 1	Identify the most common comorbidities of childhood obesity and describe their pathophysiologies. - 0
Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome.	Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome. - 5	Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome. - 4	Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome. - 3	Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome. - 2	Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome. - 1	Identify key considerations for initiating phosphorus restricted diet as a potential therapy for improving cardiovascular outcome. - 0
Identify the risk and benefit of targeted therapy and immune therapy in cancer patients.	Identify the risk and benefit of targeted therapy and immune therapy in cancer patients. - 5	Identify the risk and benefit of targeted therapy and immune therapy in cancer patients. - 4	Identify the risk and benefit of targeted therapy and immune therapy in cancer patients. - 3	Identify the risk and benefit of targeted therapy and immune therapy in cancer patients. - 2	Identify the risk and benefit of targeted therapy and immune therapy in cancer patients. - 1	Identify the risk and benefit of targeted therapy and immune therapy in cancer patients. - 0
Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies.	Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies. - 5	Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies. - 4	Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies. - 3	Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies. - 2	Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies. - 1	Identify challenges and opportunities to provide cost-effective practices in the care of the patient with hematologic malignancies. - 0
Define the Triple Aim.	Define the Triple Aim. - 5	Define the Triple Aim. - 4	Define the Triple Aim. - 3	Define the Triple Aim. - 2	Define the Triple Aim. - 1	Define the Triple Aim. - 0
Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol.	Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol. - 5	Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol. - 4	Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol. - 3	Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol. - 2	Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol. - 1	Effectively assess and document the mental status of patients in all types of clinical settings to support the clinician’s accurate determination of ethical and legal treatment protocol. - 0

Rate the following *

Scoring Key: 5=Excellent 4=Very Good 3=Good 2=Fair 1=Poor

	5	4	3	2	1
Course content.	Course content. - 5	Course content. - 4	Course content. - 3	Course content. - 2	Course content. - 1
Mario Eyzaguirre, M.D.- Pediatric Acute Respiratory Distress Syndrome	Mario Eyzaguirre, M.D.- Pediatric Acute Respiratory Distress Syndrome - 5	Mario Eyzaguirre, M.D.- Pediatric Acute Respiratory Distress Syndrome - 4	Mario Eyzaguirre, M.D.- Pediatric Acute Respiratory Distress Syndrome - 3	Mario Eyzaguirre, M.D.- Pediatric Acute Respiratory Distress Syndrome - 2	Mario Eyzaguirre, M.D.- Pediatric Acute Respiratory Distress Syndrome - 1
Francisco Sylvester, M.D. - Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now	Francisco Sylvester, M.D. - Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now - 5	Francisco Sylvester, M.D. - Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now - 4	Francisco Sylvester, M.D. - Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now - 3	Francisco Sylvester, M.D. - Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now - 2	Francisco Sylvester, M.D. - Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now - 1
Elizabeth Estrada, M.D. - Obesity in Children: It is not Their Body Weight, it is Their Health	Elizabeth Estrada, M.D. - Obesity in Children: It is not Their Body Weight, it is Their Health - 5	Elizabeth Estrada, M.D. - Obesity in Children: It is not Their Body Weight, it is Their Health - 4	Elizabeth Estrada, M.D. - Obesity in Children: It is not Their Body Weight, it is Their Health - 3	Elizabeth Estrada, M.D. - Obesity in Children: It is not Their Body Weight, it is Their Health - 2	Elizabeth Estrada, M.D. - Obesity in Children: It is not Their Body Weight, it is Their Health - 1
Jose F. Bernardo, M.D., MPH - The Connection Between Dietary Phosphorus, Cardiovascular Disease and Mortality: Rationale and Approaches to Reduce Phosphorus Levels	Jose F. Bernardo, M.D., MPH - The Connection Between Dietary Phosphorus, Cardiovascular Disease and Mortality: Rationale and Approaches to Reduce Phosphorus Levels - 5	Jose F. Bernardo, M.D., MPH - The Connection Between Dietary Phosphorus, Cardiovascular Disease and Mortality: Rationale and Approaches to Reduce Phosphorus Levels - 4	Jose F. Bernardo, M.D., MPH - The Connection Between Dietary Phosphorus, Cardiovascular Disease and Mortality: Rationale and Approaches to Reduce Phosphorus Levels - 3	Jose F. Bernardo, M.D., MPH - The Connection Between Dietary Phosphorus, Cardiovascular Disease and Mortality: Rationale and Approaches to Reduce Phosphorus Levels - 2	Jose F. Bernardo, M.D., MPH - The Connection Between Dietary Phosphorus, Cardiovascular Disease and Mortality: Rationale and Approaches to Reduce Phosphorus Levels - 1
Jorge Antunez De Mayolo, M.D., F.A.C.P. - Targeted Therapy and Checkpoint Inhibitors on the Current Treatment of Cancer	Jorge Antunez De Mayolo, M.D., F.A.C.P. - Targeted Therapy and Checkpoint Inhibitors on the Current Treatment of Cancer - 5	Jorge Antunez De Mayolo, M.D., F.A.C.P. - Targeted Therapy and Checkpoint Inhibitors on the Current Treatment of Cancer - 4	Jorge Antunez De Mayolo, M.D., F.A.C.P. - Targeted Therapy and Checkpoint Inhibitors on the Current Treatment of Cancer - 3	Jorge Antunez De Mayolo, M.D., F.A.C.P. - Targeted Therapy and Checkpoint Inhibitors on the Current Treatment of Cancer - 2	Jorge Antunez De Mayolo, M.D., F.A.C.P. - Targeted Therapy and Checkpoint Inhibitors on the Current Treatment of Cancer - 1
Cesar De Las Casas, M.D. - Emerging Therapies for Challenging Hematologic Malignancies: Are We Making Progress?	Cesar De Las Casas, M.D. - Emerging Therapies for Challenging Hematologic Malignancies: Are We Making Progress? - 5	Cesar De Las Casas, M.D. - Emerging Therapies for Challenging Hematologic Malignancies: Are We Making Progress? - 4	Cesar De Las Casas, M.D. - Emerging Therapies for Challenging Hematologic Malignancies: Are We Making Progress? - 3	Cesar De Las Casas, M.D. - Emerging Therapies for Challenging Hematologic Malignancies: Are We Making Progress? - 2	Cesar De Las Casas, M.D. - Emerging Therapies for Challenging Hematologic Malignancies: Are We Making Progress? - 1
Jose Francisco Arrascue, M.D. - The Triple Aim: Better Care, Better Health and Lower Cost	Jose Francisco Arrascue, M.D. - The Triple Aim: Better Care, Better Health and Lower Cost - 5	Jose Francisco Arrascue, M.D. - The Triple Aim: Better Care, Better Health and Lower Cost - 4	Jose Francisco Arrascue, M.D. - The Triple Aim: Better Care, Better Health and Lower Cost - 3	Jose Francisco Arrascue, M.D. - The Triple Aim: Better Care, Better Health and Lower Cost - 2	Jose Francisco Arrascue, M.D. - The Triple Aim: Better Care, Better Health and Lower Cost - 1
Alberto Goldwaser, M.D. - Forensic Considerations in the Neuropsychiatry of Delirium	Alberto Goldwaser, M.D. - Forensic Considerations in the Neuropsychiatry of Delirium - 5	Alberto Goldwaser, M.D. - Forensic Considerations in the Neuropsychiatry of Delirium - 4	Alberto Goldwaser, M.D. - Forensic Considerations in the Neuropsychiatry of Delirium - 3	Alberto Goldwaser, M.D. - Forensic Considerations in the Neuropsychiatry of Delirium - 2	Alberto Goldwaser, M.D. - Forensic Considerations in the Neuropsychiatry of Delirium - 1

Was this course fair, balanced and without commercial bias? *

Yes

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so. *

List topics related to this lecture that you want to learn more about?

Comments

Name

Stay Informed *

Have you updated your email address lately? Please update your email to ensure you receive all CME communications regarding upcoming live meetings, symposiums and online courses offerings.

Yes

If you checked "No,” please click here: *

Leave this field blank

You are here

Peruvian American Endowment Evaluation